These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34279677)

  • 1. Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
    Guerra F; Ammendola E; Ziacchi M; Aspromonte V; Pellegrino PL; Del Giorno G; Dell'Era G; Pimpini L; Santoro F; Floris R; Stronati G; Nigro G; Paolisso P; Guido A; Maglia G; Brunetti ND; Carbone A; Gravellone M; Antonicelli R; Cannone M; Accogli M; Dello Russo A; Palmisano P
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1835-1842. PubMed ID: 34279677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis.
    Rohde LE; Chatterjee NA; Vaduganathan M; Claggett B; Packer M; Desai AS; Zile M; Rouleau J; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 Oct; 8(10):844-855. PubMed ID: 32919916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
    Monzo L; Gaudio C; Cicogna F; Tota C; Petronilli V; Mennuni S; De Ruvo E; Calò L
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5690-5700. PubMed ID: 34604961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.
    Holm N; Bromage DI; Cannata A; DeCourcey J; Bhatti P; Huang M; McDonagh TA
    J Cardiovasc Med (Hagerstown); 2022 Jan; 23(1):37-41. PubMed ID: 34632983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
    Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
    Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
    Ioannou A; Metaxa S; Simon S; Mandal AKJ; Missouris CG
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):755-762. PubMed ID: 32648169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    De Vecchis R; Paccone A; Di Maio M
    Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction.
    Li BH; Fang KF; Lin PH; Zhang YH; Huang YX; Jie H
    Clin Hemorheol Microcirc; 2021; 77(4):425-433. PubMed ID: 33386797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
    Mirić D; Baković D; Eterović D; Sorić T; Čapkun V; Vuković I; Duplančić D; Barac A
    J Cardiovasc Transl Res; 2021 Apr; 14(2):290-298. PubMed ID: 32557158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.
    Corrado E; Dattilo G; Coppola G; Morabito C; Bonni E; Zappia L; Novo G; de Gregorio C
    Eur J Clin Pharmacol; 2022 Jan; 78(1):19-25. PubMed ID: 34554274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
    Zacà V
    J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):597-605. PubMed ID: 30160656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.